RE:The ones we don't have!Right?! And that's for a post-surgical, limited-to-breast-cancer drug! Now, look at Theralase's offering....
Most solid tumours...
You go into the clinic or hospital, have an infusion of TLD-1433, shine a light or an Xray on it, and go home...
and
Buh-bye! Enjoy dinner with your family tonight. Call us back in 90 days for treatment #2... And THIS Phase 2 NMIBC (but soon to be so many more applications) technology sits at less than 2 American dimes!
so... you understand my enthusiasm, yeah?
I can't even believe we're under a dollar, to be honest...
GLTY'All! Pandora wrote:
A breast cancer drug company GLSI Greenwich LifeSciences closed yesterday at $5.29 and opened this morning at $12 before running as high as $158 and then closing at $57. It is now up about $22.50 to $79.50 after hours.
Shares of Greenwich LifeSciences Inc. blasted 2,399.3% higher in very active and volatile afternoon trading Wednesday, after the Texas-based biopharmaceutical company displayed upbeat results of a Phase IIb trial for its breast cancer treatment. The stock, which has been halted no less than 20 times for volatility, was easily the biggest gainer trading on major U.S. exchanges, while trading volume of 15.9 million shares was many multiples of the full-day average of about 22,000 shares. The company said before the open that a poster presentation of five-year data for the GP2 clinical trial met all of its endpoints and showed zero recurrence of breast cancer in patients who had previously undergone surgery. The stock, which went public on Sept. 25, was now trading 2,159.7% above its $5.75 initial public offering price.